‹ All episodes

The BioInsights Podcast

Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development

June 09, 2023 Paul Byrne Season 2 Episode 6
Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
The BioInsights Podcast
Chapters
1:17
You've been working in gene therapy for a long time now. What do you see as the key learnings of the industry related to bioanalysis of in vivo therapeutic approaches?
6:24
What would you identify as the key commonalities – and the important differences – that exist in approaching bioanalysis of ex vivo gene-modified cell therapies?
9:25
How is the field of gene therapy evolving, and what new therapies and delivery methods do you see on the horizon?
13:43
Why are biodistribution, vector shedding, and transgene expression are such critical factors for ensuring the safety of cell and gene therapies?
15:27
Can you outline the key challenges associated with assessing and monitoring biodistribution and vector shedding?
20:13
What new approaches are being developed to address these challenges? And what impact is that introduction of digital PCR having?
27:18
How can the insights and best practices we've discussed today be applied to specific R&D efforts? What would your key advice be for our listeners who are working in this space?
More Info
The BioInsights Podcast
Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
Jun 09, 2023 Season 2 Episode 6
Paul Byrne

In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.

Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +
Show Notes Chapter Markers

In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.

You've been working in gene therapy for a long time now. What do you see as the key learnings of the industry related to bioanalysis of in vivo therapeutic approaches?
What would you identify as the key commonalities – and the important differences – that exist in approaching bioanalysis of ex vivo gene-modified cell therapies?
How is the field of gene therapy evolving, and what new therapies and delivery methods do you see on the horizon?
Why are biodistribution, vector shedding, and transgene expression are such critical factors for ensuring the safety of cell and gene therapies?
Can you outline the key challenges associated with assessing and monitoring biodistribution and vector shedding?
What new approaches are being developed to address these challenges? And what impact is that introduction of digital PCR having?
How can the insights and best practices we've discussed today be applied to specific R&D efforts? What would your key advice be for our listeners who are working in this space?